IFNGR1 and neoplasm: This concern is supported by a recent report showing that in vivo treatment with ruxolitinib did not suppress tumor growth and progression due to the abrogation of antitumor CD8+ T cell function through ruxolitinib-mediated inhibition of JAK1/2-dependent IFNGR1 signaling in T cells (85).